Takeda to collaborate with JCR Pharma to commercialise next-gen Hunter Syndrome therapy
Takeda to exclusively commercialize JR-141 outside the U.S. (except Japan and certain other Asia-Pacific countries) upon regulatory approval
Takeda to exclusively commercialize JR-141 outside the U.S. (except Japan and certain other Asia-Pacific countries) upon regulatory approval
Subscribe To Our Newsletter & Stay Updated